explore -WSS

explore

author：explore 2025-09-30 22:05:38 - browse：38696

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Coercive sterilizations revealed by STAT prompt outrage

WSS

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Alabama IVF ruling threatens families facing fatal genetic disease

How faith leaders like me can help address America's obesity epidemic

STAT readers on older presidents, polypills, Medicare, and more

Medicare inequities exacerbate Puerto Rico’s health disparities

NIH study of ME/CFS points to clear biological hallmarks

leisure time

explore

focus

Wildfire smoke exposes gaps in outdoor worker protections

Medical device trials still don't enroll enough women, study finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Essentially witchcraft:' A former naturopath takes on the field

United colonoscopy coverage change 'may cost lives,' doctors say

ALS patient reclaims some autonomy thanks to wearable 'robot'

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Trump demands the U.S. pay no more for drugs than other countries … again

A solution to the after

focus

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

ALS patient reclaims some autonomy thanks to wearable 'robot'

Coercive sterilizations revealed by STAT prompt outrage

The system is set up to fail children with medical complexity

Coercive sterilizations revealed by STAT prompt outrage

entertainment

knowledge

entertainment

hotspot